檢索結果 - Mark Kirschbaum

Refine Results
  1. 1
    SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells

    SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells 由 A Scuto, Mark Kirschbaum, Ralf Buettner, Maciej Kujawski, J Cermák, Peter Atadja, Richard Jove

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

    A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a... 由 Mark Kirschbaum, Kenneth A. Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone, Joseph M. Tuscano, Edward M. Newman

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

    A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 由 Mark Kirschbaum, Bryan Goldman, Jasmine Zain, James R. Cook, Lisa M. Rimsza, Stephen J. Forman, Richard I. Fisher

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen

    HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen 由 Nainong Li, Dongchang Zhao, Mark Kirschbaum, Chunyan Zhang, Chia-Lei Lin, Иван Тодоров, Fouad Kandeel, Stephen J. Forman, Defu Zeng

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

    Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels 由 Leo Kretzner, Anna Scuto, Pamela M. Dino, Claudia Kowolik, Jun Wu, Patrick Ventura, Richard Jove, Stephen J. Forman, Yun Yen, Mark Kirschbaum

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells

    The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells 由 Anna Scuto, Mark Kirschbaum, Claudia Kowolik, Leo Kretzner, Ágnes Juhász, Peter Atadja, Vinod Pullarkat, Ravi Bhatia, Stephen J. Forman, Yun Yen, Richard Jove

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

    Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome 由 Eldad J. Dann, Rachel Bar‐Shalom, Ada Tamir, Nissim Haim, Menachem Ben‐Shachar, Irit Avivi, Tzila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, Ron Epelbaum

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

    A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma 由 Robert Chen, Paul Frankel, Leslie Popplewell, Tanya Siddiqi, Nora Ruel, A Rotter, Sandra H. Thomas, Michelle Mott, Nitya Nathwani, Myo Htut, AP Nademanee, Stephen J. Forman, Mark Kirschbaum

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

    Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas 由 Fan Yang, Timothy Van Meter, Ralf Buettner, Michael Hedvat, Wei Liang, Claudia Kowolik, Nilesh Mepani, Janni Mirosevich, Sangkil Nam, Mike Y. Chen, Gary Tye, Mark Kirschbaum, Richard Jove

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome 由 Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph Eid, Gregory M. Lubiniecki, Jean–Pierre J. Issa

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant a... 由 Shimon Slavin, Arnon Nagler, E Naparstek, Y. Kapelushnik, Memet Aker, Gabriel Cividalli, Gàbor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben‐Tal, A Eldor, Reuven Or

    出版 1998
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant a... 由 Shimon Slavin, Arnon Nagler, E Naparstek, Y. Kapelushnik, Memet Aker, Gabriel Cividalli, Gàbor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben‐Tal, A Eldor, Reuven Or

    出版 1998
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma 由 Mark Kirschbaum, Paul Frankel, Leslie Popplewell, Jasmine Zain, Maria Delioukina, Vinod Pullarkat, Deron Matsuoka, Bernadette Pulone, A Rotter, Igor Espinoza‐Delgado, Auayporn Nademanee, Stephen J. Forman, David R. Gandara, Edward M. Newman

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

    A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma 由 Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao‐Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, Edward M. Newman

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

    Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression 由 Yasuhiro Oki, Daniela Buglio, J. Zhang, Y Ying, Shouhao Zhou, Anna Sureda, Dina Ben‐Yehuda, Pier Luigi Zinzani, H. Miles Prince, Simon J. Harrison, Mark Kirschbaum, Patrick B. Johnston, Angela Shen, Bastian von Tresckow, Anas Younes

    出版 2014
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  16. 16
    Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma 由 Richard Piekarz, Robin Frye, H. Miles Prince, Mark Kirschbaum, Jasmine Zain, Steven L. Allen, Elaine S. Jaffe, Alexander Ling, Maria L. Turner, Cody J. Peer, William D. Figg, Seth M. Steinberg, Sonali M. Smith, David Joske, Ian A. Lewis, Laura F. Hutchins, Michael Craig, Antonio Tito Fojo, James R. Wright, Susan E. Bates

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma 由 Richard Piekarz, Robin Frye, Maria L. Turner, John J. Wright, Steven L. Allen, Mark Kirschbaum, Jasmine Zain, H. Miles Prince, John P. Leonard, Larisa J. Geskin, Craig B. Reeder, David Joske, William D. Figg, Erin R. Gardner, Seth M. Steinberg, Elaine S. Jaffe, Maryalice Stetler‐Stevenson, Stephen Lade, Antonio Tito Fojo, Susan E. Bates

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

    Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease 由 Francisco López, Pablo Parker, Auayporn Nademanee, Roberto Rodríguez, Zaid Al‐Kadhimi, Ravi Bhatia, Sandra Cohen, Peter Falk, Henry C. Fung, Mark Kirschbaum, Amrita Krishnan, Neil Kogut, Arturo Molina, Ryotaro Nakamura, Margaret O’Donnell, Leslie Popplewell, Vinod Pullarkat, Joseph Rosenthal, Firoozeh Sahebi, Eileen Smith, David S. Snyder, George Somlo, Ricardo Spielberger, Anthony S. Stein, Robert Sweetman, Jasmine Zain, Stephen J. Forman

    出版 2005
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial 由 Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Díaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poiré, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab Atallah, Philip A. Dy, Sachdev Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

    A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in pati... 由 Auayporn Nademanee, Stephen J. Forman, Arturo Molina, Henry C. Fung, David Smith, Andy Dagis, Cheuk Kwok, Dave Yamauchi, Anne-Line Anderson, Peter Falk, Amrita Krishnan, Mark Kirschbaum, Neil Kogut, Ryotaro Nakamura, Margaret O’Donnell, Pablo Parker, Leslie Popplewell, Vinod Pullarkat, Roberto Rodríguez, Firoozeh Sahebi, Eileen Smith, David S. Snyder, Anthony S. Stein, Ricardo Spielberger, Jasmine Zain, Christine A. White, Andrew Raubitschek

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: